4th Quarter - Report

ALFRED W. CORS, JR for RETIRESAFE

Firm
Client
Income
$15,510
Expenses
—

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Retirement RET

Support H.R. 1086, the CPI for Seniors Act Support the Social Security and Medicare Protection Act (H.R. 1630) Oppose any effort to establish a chained-CPI to determine annual Social Security COLAs.

LobbyistCovered position, as disclosed
ALFRED W CORS —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 1086 (112th), H.R. 1630 (112th)

Health Issues HCR

Support the speedy implementation of the National Alzheimer's Project Act (NAPA) by HHS, and support Leaders Engaged on Alzheimer's Disease (LEAD) recommendations as to how to proceed. Support repeal of Section 6001 of the PPACA and remove all restrictions on physician-owned hospitals. (Support H.R. 1159 and H.R. 1186) Support extensive clinical trials, manufacturing inspections and post-market surveillance for all biosimilar drugs. Support higher PDUFA fees for biosimilar drugs to pay for the additional safeguards needed. Oppose federal budget cuts that would increase co-payments for home health care services under Medicare and/or Medicaid. Support all legislative and regulatory action to modernize the FDA and to speed new cures and therapies to patients. Support the Preservation of Access to Osteoporosis Testing for Medicare Benificiaries Act of 2011 (S. 1096, H.R. 2020) Support Leaders Engaged on Alzheimer's Disease (LEAD) FY 2012 funding proposals in the amount of for $35 billion for the National Institutes of Health (NIH), $1.4 billion for the National Institute on Aging (NIA), $100 million for the Cures Acceleration Network (CAN), $11.46 million for the Alzheimer's Disease Supportive Services Program (ADSSP), $192 million for the National Family Caregiver Support Program (NFCSP), $50 million for the Lifespan Respite Care Program (LRCP), and$2.744 billion for the Food and Drug Administration (FDA), as well as $2 million for the Missing Alzheimer's Disease Patient Alert Program and $750,000 to organize and host a high-level meeting to focus on the global Alzheimer's disease crisis. Oppose proposals that would reduce Medicare payments for providers of drugs and biologics under Medicare Part B. Support the proposed Prescription Drug User Fee Act Reauthorization Agreement (PDUFA-V) now under consideration by the Congress for reauthorization. Support an extension of the Therapeutic Discovery Project Tax Credit (I.R.C. 48D). Oppose the proposed merger between pharmacy benefit managers (PBM) Medco Health Solutions (Medco) and Express Scripts, Inc. (ESI). Support the development of clearly-defined, comprehensive, patient-centric Essential Health Benefits rules under the Affordable Care Act. Support he Counterfeit Drug Penalty Enhancement Act of 2011.

LobbyistCovered position, as disclosed
ALFRED W CORS —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE

Bills named: H.R. 1159 (112th), H.R. 2020 (112th), S. 1096 (112th), H.R. 1186 (112th)

Medicare/Medicaid MMM

Support American Society of Consultant Pharmacists and "Short Cycle Dispensing Coalition" recommendations regarding the delay and study of new long-term care pharmacy dispensing rules and the impact of those rules on Medicare and Medicaid patients. Support H.R. 1055, the Part D Off-Label Prescription Drug Parity Act. Continue to oppose cuts to Medicare benefits, and continue to oppose the Independent Payment Advisory Board (IPAB). Support Medicare Access for Patients Rx (MAPRx) recommendations to Centers for Medicare and Medicaid Services (CMS) all regarding Medicare Part D. Those MAPRx recommendations are in regard to: Improved beneficiary protections; Better, more transparent Specialty Tier guidance including the threshold for inclusion on this tier and the inclusion of data for newly approved drugs; New, more realistic co-pay thresholds; Automatic disenrollment from Special Needs Plans; Proposed plan rating criteria; and Approval of six-tier formularies. These are in addition to MAPRx concerns regarding: The Part D Medicare appeals process and the handling of enrollee complaints; Drug dispensing rules for Part D beneficiaries in long-term care facilities; the Authority to deny bids and potential additional restrictions; and Compound Drug Policy. Support repeal of IPAB (H.R. 452). Support changes to the Medicare Shared Savings Program: Accountable Care Organization (ACO) proposed regulations, to provide additional safeguards to guarantee patient access to needed care, and to ensure that ACO's support the adoption of new treatments and cures for patients. Also support the addition of new Alzheimer's disease focused ACO quality measures, new ACO measures of provider evidence of competency in Geriatrics and Dementia, as well as a guarantee that Alzheimer's and Dementia patients under ACO care will have access to the newest pharmaceutical and biological treatments. Support repeal of Section 6001 of the PPACA and remove all restrictions on physician-owned hospitals. (Support H.R. 1159 and H.R. 1186) Oppose federal budget cuts that would increase co-payments for home health care services under Medicare and/or Medicaid Support the Preservation of Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2011 (S. 1096 and H.R. 2020) Support MAPRx suggestions to CMS on Medicare Part D Prescription Drug Program regarding new beneficiary-friendly point-of-sale notices that address problems in filling prescriptions and clear, instructive remedies for beneficiaries. Oppose proposals that would reduce payments to providers of drugs and biologics under Medicare Part B. Oppose proposals to increase Medicare Part D cost-sharing, raise Part D coinsurance, and/or freeze income thresholds. Oppose efforts to require Medicaid-type drug rebates from any Medicare Part D providers and all other kinds of mandated or negotiated Part D price controls that will harm beneficiaries and increase costs in other areas of Medicare. Support efforts to focus Medicare cost-saving efforts on eliminating improper payments, waste, fraud, and abuse first -- before cutting benefits, cutting payments to providers, or raising premium and coinsurance costs for beneficiaries. Support H.R. 3613 - Medicare Part D Beneficiary Appeals Fairness Act. Urged the "Super Committee" to resist proposals to erode beneficiary protections in Part D that ensure broad and accessible prescription drug formularies.

LobbyistCovered position, as disclosed
ALFRED W CORS —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 2020 (112th), H.R. 3613 (112th), H.R. 1186 (112th), H.R. 1055 (112th), H.R. 452 (112th), S. 1096 (112th), H.R. 1159 (112th)

Budget/Appropriations BUD

Support the Social Security and Medicare Protection Act (now H.R. 1630). Support full and increased funding for the Low Income Energy Assistance Program (LIHEAP) for FY 2012 (at least $5.1 billion). Support full and increased funding for National Institutes of Health (NIH) and theNational Institute on Aging (NIA). Oppose federal budget cuts that would increase co-payments for home health care services under Medicare and/or Medicaid Oppose any effort to establish a chained-CPI to determine annual Social Security COLAs. Support Leaders Engaged on Alzheimer's Disease (LEAD) FY 2012 funding proposals in the amount of for $35 billion for the National Institutes of Health (NIH), $1.4 billion for the National Institute on Aging (NIA), $100 million for the Cures Acceleration Network (CAN), $11.46 million for the Alzheimer's Disease Supportive Services Program (ADSSP), $192 million for the National Family Caregiver Support Program (NFCSP), $50 million for the Lifespan Respite Care Program (LRCP), and$2.744 billion for the Food and Drug Administration (FDA), as well as $2 million for the Missing Alzheimer's Disease Patient Alert Program and $750,000 to organize and host a high-level meeting to focus on the global Alzheimer's disease crisis. Oppose all harmful cuts to Medicare designed to provide "deficit reduction."

LobbyistCovered position, as disclosed
ALFRED W CORS —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1630 (112th)

Consumer Issues/Safety/Products CSP

Support the Motor Vehicle Owners Right to Repair Act (now H.R. 1449). Support Access to Repair Parts legislation.

LobbyistCovered position, as disclosed
ALFRED W CORS —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Bills named: H.R. 1449 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.